What's Going On With Novavax Stock?
Shares of Novavax (NASDAQ: NVAX) have been extremely volatile as the market tries to value the company's COVID-19 vaccine. In January of last year, the company's stock was valued at $4 a share. The stock zoomed higher when COVID-19 hit, the tiny company introduced its vaccine candidate, and saw early success in clinical trials. After the biotech reported positive phase 3 data earlier this year, the stock hit $330 a share.
Since then the stock has crashed about 60%, falling to a recent price of $134 as of this writing. Why has the stock been so volatile, and where will it go next? Let's dig in.
Image source: Getty Images
Source Fool.com
